Floatz logo

Muromonab-Cd3

Kidney Neoplasms

National Cancer Institute (NCI)monoclonal_antibodyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Kidney Neoplasms cohort.

Asset / SponsorPhaseRating
Axitinib
Pfizer
Phase 3BB
Ipilimumab
Pfizer
Phase 4BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Inno-206
Merck Sharp & Dohme LLC
Phase 2BB
Sorafenib
Pfizer
Phase 3B

View all 50 →

Same molecule, other indications

Muromonab-Cd3 is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
Myelodysplastic Syndrome (MDS)Dormant
BB
Indicative ·
69 / 100
View asset →
paroxysmal nocturnal hemoglobinuriaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →